Literature DB >> 16382259

Intramyocardial injection of allogenic bone marrow-derived mesenchymal stem cells without immunosuppression preserves cardiac function in a porcine model of myocardial infarction.

Raj R Makkar1, Matthew J Price, Michael Lill, Malka Frantzen, Kaname Takizawa, Thomas Kleisli, Jie Zheng, Saibal Kar, Robert McClelan, Takeshi Miyamota, Justin Bick-Forrester, Michael C Fishbein, Prediman K Shah, James S Forrester, Behrooz Sharifi, Peng-Sheng Chen, Mohammed Qayyum.   

Abstract

BACKGROUND: We investigated the efficacy of directly injected allogenic bone marrow-derived mesenchymal stem cells in improving left ventricular function in a porcine model of myocardial infarction.
METHODS: Left ventricular infarction was created in 16 adult Yorkshire pigs by coil embolization and thrombotic occlusion distal to the second diagonal artery. One month after myocardial infarction was induced, the animals were randomized to either direct injection of allogenic mesenchymal stem cells or sham treatment (culture medium). Allogenic bromodeoxyuridine-labeled mesenchymal stem cells (2 +/- 0.1 x 10(8)) were directly injected into the infarct and peri-infarct areas during an open chest procedure. No immunosuppressive therapy was used. The left ventricular function was measured using serial biplane left ventricular angiography at baseline, 30, 60, and 90 days before sacrifice. Mesenchymal stem cells were localized using bromodeoxyuridine, and differentiation of mesenchymal stem cells was assessed by confocal microscopic colocalization of bromodeoxyuridine with immunofluorescent antibodies specific for cardiomyocytes (troponin I and MF-20) and endothelial cells (von Willebrand factor).
RESULTS: Mesenchymal stem cells labeled with bromodeoxyuridine engrafted the peri-infarct zone and colocalized with both cardiomyocyte-specific and endothelial cell-specific immunofluorescence. No intramyocardial bromodeoxyuridine was observed in sham-treated animals. At the time of the mesenchymal stem cell injection 30 days after myocardial infarction, the left ventricular ejection fraction (LVEF) was 58% +/- 3% in mesenchymal stem cell-treated pigs and 56% +/- 2% in sham-treated pigs (P = NS). LVEF deteriorated progressively thereafter in untreated pigs (8.5% and 10.5% decline at 60 days and 90 days after myocardial infarction, respectively), but was preserved in mesenchymal stem cell-treated pigs (2.1% increase and -2.0% decline at 60 and 90 days post-MI respectively) (P < .05).
CONCLUSIONS: Direct intramyocardial injection of mesenchymal stem cells results in successful intramyocardial engraftment and differentiation into cardiomyocytes and endothelial cells and preserves left ventricular function after myocardial infarction in pigs.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16382259     DOI: 10.1177/107424840501000403

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol Ther        ISSN: 1074-2484            Impact factor:   2.457


  39 in total

1.  Delivery of gelfoam-enabled cells and vectors into the pericardial space using a percutaneous approach in a porcine model.

Authors:  D Ladage; I C Turnbull; K Ishikawa; Y Takewa; K Rapti; C Morel; I Karakikes; L Hadri; J Müller-Ehmsen; K D Costa; R J Hajjar; Y Kawase
Journal:  Gene Ther       Date:  2011-04-21       Impact factor: 5.250

Review 2.  Protein localization in the plant Golgi apparatus and the trans-Golgi network.

Authors:  C Saint-Jore-Dupas; V Gomord; N Paris
Journal:  Cell Mol Life Sci       Date:  2004-01       Impact factor: 9.261

3.  Isolation, characterization and differentiation potential of cardiac progenitor cells in adult pigs.

Authors:  A Vanelli; G Pennarossa; S Maffei; B G Galvez; G B Galvez; G Cossu; M Rahaman; F Gandolfi; T A L Brevini
Journal:  Stem Cell Rev Rep       Date:  2012-09       Impact factor: 5.739

Review 4.  Stem cell death and survival in heart regeneration and repair.

Authors:  Eltyeb Abdelwahid; Audrone Kalvelyte; Aurimas Stulpinas; Katherine Athayde Teixeira de Carvalho; Luiz Cesar Guarita-Souza; Gabor Foldes
Journal:  Apoptosis       Date:  2016-03       Impact factor: 4.677

Review 5.  Stem cells in the heart: what's the buzz all about? Part 2: Arrhythmic risks and clinical studies.

Authors:  Rachel Ruckdeschel Smith; Lucio Barile; Elisa Messina; Eduardo Marbán
Journal:  Heart Rhythm       Date:  2008-02-15       Impact factor: 6.343

6.  Biomechanical Screening of Cell Therapies for Vocal Fold Scar.

Authors:  Rebecca S Bartlett; Joel D Gaston; Tom Y Yen; Shuyun Ye; Christina Kendziorski; Susan L Thibeault
Journal:  Tissue Eng Part A       Date:  2015-07-22       Impact factor: 3.845

Review 7.  [Surgical intramyocardial stem cell therapy for chronic ischemic heart failure].

Authors:  Alexander Kaminski; Peter Donndorf; Christian Klopsch; Gustav Steinhoff
Journal:  Herz       Date:  2010-08       Impact factor: 1.443

8.  Mechanotransduction of vocal fold fibroblasts and mesenchymal stromal cells in the context of the vocal fold mechanome.

Authors:  Rebecca S Bartlett; Joel D Gaston; Shuyun Ye; Christina Kendziorski; Susan L Thibeault
Journal:  J Biomech       Date:  2018-12-07       Impact factor: 2.712

Review 9.  Pre-transplantation specification of stem cells to cardiac lineage for regeneration of cardiac tissue.

Authors:  Maritza Mayorga; Amanda Finan; Marc Penn
Journal:  Stem Cell Rev Rep       Date:  2009-01-30       Impact factor: 5.739

10.  Cell tracking and therapy evaluation of bone marrow monocytes and stromal cells using SPECT and CMR in a canine model of myocardial infarction.

Authors:  Gerald Wisenberg; Katie Lekx; Pam Zabel; Huafu Kong; Rupinder Mann; Peter R Zeman; Sudip Datta; Caroline N Culshaw; Peter Merrifield; Yves Bureau; Glenn Wells; Jane Sykes; Frank S Prato
Journal:  J Cardiovasc Magn Reson       Date:  2009-04-27       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.